GlassScriptPhysician profile
Vinay Nakhate
NPI 1386767697
$1,953.70
in general payments reported to CMS, 2019-2025
31 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $161 · 2021: $202 · 2022: $258 · 2023: $330 · 2024: $340 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $289.70 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.05 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $161.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $155.91 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $132.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $132.56 | 2020-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $127.17 | 2019-2024 | Xarelto |
| Abbvie INC. | $73.77 | 2022-2024 | |
| Pfizer INC. | $68.98 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.52 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $57.73 | 2022-2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $50.23 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $49.99 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $45.27 | 2024-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $44.75 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.55 | 2024-2025 | Otezla, Repatha, Otezla |
| Boston Scientific Corporation | $31.09 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $29.89 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $28.62 | 2021-2025 | Nuplazid |
| Soleno Therapeutics, INC. | $24.88 | 2025 | Vykat Xr |
| Verona Pharma, INC. | $23.88 | 2025 | Ohtuvayre |
| Dexcom, INC. | $18.13 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $16.60 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2025 | Austedo Xr |
| Philips North America LLC | $15.50 | 2019 | |
| Glaxosmithkline, LLC. | $14.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.30 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.03 | 2023 | Quviviq |
| Sun Pharmaceutical Industries INC. | $12.60 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Nakhate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.